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Background. The aim of this investigation is to study the relationship between gastric morphology and serum biomarkers before
and after Helicobacter pylori eradication. Methods. First-degree relatives of gastric cancer patients underwent gastroscopy before
and 2.5 years afterH. pylori eradication.Themorphological changes in two categories (normal tomild andmoderate to severe) were
compared with level of pepsinogens I and II before eradication (𝑛 = 369), after eradication (𝑛 = 115), and in those with persistent
infection (𝑛 = 250). Results: After eradication, pepsinogen I decreased to 70% and pepsinogen II to 45% of the previous values.
Unlike pepsinogen II and pepsinogen I to II ratio that were affected by the severity of inflammation and atrophy in corpus in all
groups, pepsinogen I generally did not change. After eradication, subjects with high mononuclear infiltration in corpus had lower
pepsinogen I (54 versus 77.1 𝜇/mL), higher pepsinogen II (9.4 versus 6.9𝜇/mL), and lower ratio (7.9 versus 11.6) than those without
(𝑃 < 0.05). Conclusion. Pepsinogen II is a good marker of corpus morphological changes before and after H. pylori eradication.
1. Introduction
Serum pepsinogens I and II are increasingly used as markers
of the advanced stages of atrophic gastritis being at risk of
gastric cancer [1–3], since they were reported to be produced
in gastric mucosa by authors from Germany and USA [4–
7]. Pepsinogen I is secreted in corporal mucosa by chief
cells whereas pepsinogen II is made by the epithelium of the
upper and lower parts of stomach including the duodenal
bulb [6, 7]. The production of pepsinogen I is considerably
reduced or abolished in case of the atrophy of corpus mucosa
and loss of chief cells as well as the parietal cells [1]. On
the other hand, serum level of pepsinogen II increases when
gastric mucosa is infiltrated by neutrophils and mononuclear
cells in antrum as a result of H. pylori infection and its
extension into the upper stomach, as we reported earlier with
others [8–11]. Thus, the ratio of pepsinogen I to II decreased
further in association with low pepsinogen I by advanced
atrophic gastritis in corpus. Several studies have reported a
decrease of pepsinogen I and more remarkably pepsinogen
II few weeks after successful eradication of H. pylori asso-
ciated with the regression of inflammatory markers [12–21],
suggesting that the H. pylori-induced heavy inflammation is
a strong stimulus for the synthesis of these biomarkers.There
are no systematic studies of the morphological changes of
gastric mucosa and its topography with the measurement of
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pepsinogens I and II and their ratio before and afterH. pylori
eradication, when regression of inflammatory cells occurs.
The aim of this study is to establish this relation in first-
degree relatives of gastric cancer patients, who underwent
H. pylori eradication in a double blind randomized con-
trolled study for the effect of H. pylori eradication on the
morphological changes of gastric mucosa. The results of the
morphological changes have already been published [22].
After H. pylori eradication, the neutrophil cell infiltration
regressed completely and the mononuclear cell infiltration
like atrophy regressed partially. However, no change of
intestinal metaplasia occurred in antrum and corpus of those
with successful eradication.
2. Materials and Methods
Fasting blood samples were taken from first-degree relatives
of patients with gastric cancer at the beginning of the study
and 2.5 years later and were stored at −70∘C. Then, all
cases underwent esophagogastroduodenoscopy and 5 biop-
sies were taken in patients with no significant endoscopic
lesions including two from antrum (one from the lesser
curvature and one from the greater curvature) and 3 from the
corpus (one from lesser, one from the greater curvature, and
one from the fornix of stomach). One specimen was taken
from the incisura angularis for rapid urease test (RUT). All
specimens were fixed in formalin stained by Haematoxylin
and eosin (H&E) and Giemsa when necessary and scored on
the basis of the updated Sydney classification [23].
The subjects with no significantmacroscopic findings and
with H. pylori infection were allocated by block randomiza-
tion into two groups. One group received (𝑛 = 261) eradi-
cation therapy (ranitidine 300mg BID, furazolidone 500mg
BID, metronidazole 500mg BID, and bismuth subcitrate
240mg BID, all for 2 weeks) and the other received identical
placebos (𝑛 = 260). Two and a half years later, the patients
underwent a second gastroscopy and biopsies were taken in
the same way as described above.
The severity of neutrophil or mononuclear cell infiltra-
tion, atrophy, and intestinal metaplasia (IM) was classified
in 4 grades (none = 1, slight = 2, moderate = 3, and
severe = 4). H. pylori infection was considered absent on
the basis of negative rapid urease test (RUT) and negative
histology. H. pylori infection was considered positive, when
RUT was positive and H. pylori was detected histologically
in at least one of five specimens. The most severe finding in
specimens from antrum and corpus was taken as the grade
of severity in that anatomical location. The pathologists were
unaware of the type of therapy that each group received.
The severity of morphological changes was categorized in
two groups: normal or slight changes were considered as
low grade and moderate or severe ones as high grade. The
levels of both biomarkers and the ratios of pepsinogens I to
II were calculated in two categories in low and high grade
of neutrophil, mononuclear cell infiltration, atrophy, and
intestinal metaplasia (IM) separated in antrum and corpus
before and 2.5 years later in successfully eradicated subjects
in the control group with persistent infection and from the
therapy group with failed eradication.The pepsinogens I and
II were measured at the same time in all serum samples
with ELISA kits (Biohit, Helsinki, Finland). The protocol of
clinical trial was approved in 2001 by the Ethics Committee of
Shariati Hospital affiliated with Tehran University of Medical
Sciences.
3. Statistical Analyses
Statistical analysis was performed by SPSS version 15. Two-
sided 𝑡-test was done to compare the pepsinogen levels
between groups. 𝑃 < 0.05 was considered as significant. As
no normal distribution of pepsinogen datawas found in some
groups of high or low levels ofmorphological changes,Mann-
Whitney 𝑈 test was performed for the evaluation. Median
and interquartile ranges as 25–75 percentiles are provided
when appropriate. The study protocol of clinical trial was
registered in the WHO Approved Committee of the Iranian
Clinical Trial Registry (http://www.irct.ir/index.php) with
registration number: IRCT138802071852N1. The project was
funded by DDRI, Tehran University of Medical Sciences.
4. Results
Out of 989 subjects, all first-degree relatives of gastric
cancer patients, 468 subjects, were excluded (108 subjects
had macroscopic lesions, 17 had no definite histological
diagnosis, 243 had no H. pylori infection, 60 subjects had
antrum restricted gastritis, and 40 refused to participate).
The remaining 521 subjects with H. pylori infection (mean
age of 47.8 ± 6.7; range 38–70 years; 256 males and 265
females) participated in the study. 261 received therapy and
260 received placebo. 402 subjects participated in a followup
2.5 years later. Data for biomarkers was available for 393
subjects. 250 subjects hadH. pylori infectionwhen the second
endoscopy was conducted (168 from the placebo group with
persistent infection and 82 from the therapy group with
failed eradication). 119 subjects from the therapy group had
no infection. 20 subjects from the placebo group, whose
infection has disappeared probably due to the intake of
antibiotics that were given to them by their family physicians,
were not included due to the unknown length of eradication
period. Complete data of serumbiomarkers andmorphologi-
cal findings existed for 115 eradicated and 245 non-eradicated
subjects.
The levels of serum biomarkers in all subjects before
eradication and their level after successful eradication, failed
eradication, or persistent infection are presented in Table 1.
The level of pepsinogens I and II and their ratio did not
change for those patients with persistent infection 2.5 years
later. In the subjects with successful eradication, pepsinogen
I decreased to 70% and pepsinogen II to 45% in comparison
to the values before eradication.
The median values for pepsinogen I and pepsinogen II,
as well as their ratio in the two categories of severity of
morphological characteristics, are presented for the whole
group before eradication in Table 2, for those with successful
eradication in Table 3, and for those with failed eradication in
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Table 1: Levels∗ of serum pepsinogens I, II and their ratio in three groups: before (𝑛 = 369) and after successful eradication of H. pylori
(𝑛 = 115) in the treatment group and H. pylori non-eradicated group (control group, 𝑛 = 168 & failed eradication in treatment group,
𝑛 = 82).
Groups Pepsinogen I (𝜇g/mL) Pepsinogen II (𝜇g/mL) Pepsinogen I to II ratio
All subjects (𝑛 = 369)
Before intervention 121.2 ± 57.1 18.2 ± 11.4 8.3 ± 5.6
H. pylori eradicated group (𝑛 = 115)
Before 120.7 ± 57.8 18.2 ± 11.0 7.8 ± 5.0
After 2.5 years 85.2 ± 42.3∗∗ 8.1 ± 4.2∗∗ 12.2 ± 7.4∗∗
H. pylori noneradicated group (𝑛 = 250)
After 2.5 years 128.1 ± 57.2 19.7 ± 15.1 8.5 ± 4.9
∗All pepsinogen levels are presented as mean ± SD.
∗∗
𝑃 < 0.001 compared with initial values.
Table 2: Concentrations of pepsinogen I, pepsinogen II, and pepsinogen I to II ratio according to the severity of histological categories1 in
antrum and corpus in first-degree relatives of patients with gastric adenocarcinoma beforeH. pylori eradication (𝑛 = 371).
Pepsinogen I (𝜇g/mL) Pepsinogen II (𝜇g/mL) Pepsinogen ratio
Median IQR2 Median IQR Median IQR
Antrum
Neutrophil cell
infiltration
High 𝑛 = 221 109.1 83.6–160.8 16.3∗ 10.5–24.3 6.8 5.0–9.4
Low 𝑛 = 148 105.3 74.1–154.9 14.0 9.2–21.6 7.5 5.3–10.3
Mononuclear cell
infiltration
High 𝑛 = 323 106.2 81.8–157.4 15.8∗ 10.2–23.9 7.0 5.2–9.4
Low 𝑛 = 46 117.9 66.7–168.2 11.6 9.0–20.7 8.3 4.1–13.5
Atrophy High 𝑛 = 76 100.3 74.6–158.0 16.4 10.4–23.0 6.2
∗ 5.0–8.7
Low 𝑛 = 293 109.1 81.9–158.7 15.0 9.8–23.7 7.5 5.2–10.4
Intestinal metaplasia High 𝑛 = 32 89.8 64.9–152.3 15.4 11.4–19.9 6.0
∗ 4.1–8.0
Low 𝑛 = 337 108.3 82.1–160.2 15.3 9.7–23.9 7.2 5.2–10.0
Corpus
Neutrophil cell
infiltration
High 𝑛 = 194 109.2 85.4–156.6 17.1∗∗∗ 11.3–26.5 6.4∗∗∗ 4.7–8.4
Low 𝑛 = 175 104.6 76.4–162.4 13.0 8.9−20.3 8.0 5.6–11.2
Mononuclear cell
infiltration
High 𝑛 = 276 105.9 79.2–157.0 17.0∗∗∗ 10.6−25.5 6.5∗∗∗ 4.7–8.5
Low 𝑛 = 93 112.5 80.3–161.1 11.6 8.7−18.0 9.1 6.4–13.1
Atrophy High 𝑛 = 107 103.0 77.8–162.6 17.2
∗ 11.4−24.7 6.2∗∗ 4.7–8.6
Low 𝑛 = 262 108.4 80.9–157.9 14.2 9.5−23.2 7.5 5.3–10.5
Intestinal metaplasia High 𝑛 = 14 184.4 58.8–263.2 24.9
∗ 13.5−41.9 5.1∗ 4.1–8.2
Low 𝑛 = 355 106.9 79.7–155.5 15.0 9.9−23.4 7.1 5.2–10.0
1Low score: normal or mild changes; high score: moderate or marked changes.
2IQR: interquartile range expressed as percentile 25–75.
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 when pepsinogen concentrations (or pepsinogen ratio) were compared in groups of high and low histology scores
(Mann-Whitney 𝑈 test).
Table 4. Two and a half years later, considerable proportion of
patients with persistent infection lost their inflammatory cells
both in antrum and corpus.
No relationship was found between the severity of histo-
logical changes in antrum and the level of pepsinogen I in any
of the three groups before or after successful eradication or in
those with persistent infection (Tables 2, 3, and 4).
In contrast, pepsinogen II and mostly pepsinogen I
to pepsinogen II ratio were affected by the severity of
inflammatory cells in antrum and corpus before eradication
(Table 2).
After successful eradication, severe neutrophil cell infil-
tration regressed almost completely in antrum and corpus,
while mononuclear cell infiltration remained severe in one-
sixth of the eradicated subjects both in antrum and corpus.
Thus, pepsinogen II remained slightly high and the ratio of
pepsinogen I to pepsinogen II became lower in the subjects
with high grade of mononuclear cell infiltration in corpus
compared with low grade. The subjects with high grade of
atrophy in corpus had significant increase of pepsinogen II
level compared with the low grade (𝑃 < 0.05) (Table 3).
With the presence of high grade IM in corpus before
eradication, pepsinogen II seemed to be high and the ratio of
pepsinogen I to pepsinogen II to be low (Table 2), but, after
successful eradication, pepsinogen I and the ratio of pepsino-
gen I to pepsinogen II levels decreased more compared with
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Table 3: Concentrations of pepsinogen I, pepsinogen II, and pepsinogen I to II ratio by histological categories1 in antrum and corpus in
first-degree relatives of patients with gastric adenocarcinoma after successful H. pylori eradication (𝑛 = 115).
Pepsinogen I (𝜇g/mL) Pepsinogen II (𝜇g/mL) Pepsinogen ratio
Median IQR2 Median IQR Median IQR
Antrum
Neutrophil cell
infiltration
High 𝑛 = 1 32.5 — 13.5 — 2.4 —
Low 𝑛 = 114 77.3 59.0–103.5 7.1 5.3–9.5 11.3 7.9–14.9
Mononuclear
cell infiltration
High 𝑛 = 25 66.5 52.3–106.8 6.8 5.2–9.9 12.2 6.1–15.3
Low 𝑛 = 90 80.0 59.4–103.5 7.2 5.3–9.7 10.7 8.0–14.9
Atrophy High 𝑛 = 10 82.8 63.1–119.5 6.5 5.0–8.4 13.2 10.8–16.5
Low 𝑛 = 105 77.1 57.6–103.0 7.2 5.4–9.7 10.7 7.9–14.5
Intestinal metaplasia High 𝑛 = 10 66.4 58.5–91.3 5.4 4.9–10.3 13.1 10.6–14.4
Low 𝑛 = 105 77.5 58.2–104.0 7.3 5.5–9.7 10.7 7.8–15.7
Corpus
Neutrophil cell
infiltration
High 𝑛 = 0 — — — — — —
Low 𝑛 = 115 77.1 58.7–103.1 7.1 5.3–9.6 11.2 7.9–14.8
Mononuclear
cell infiltration
High 𝑛 = 19 54.0∗ 35.6–94.8 9.4 5.8–11.6 7.9∗∗ 3.8–12.6
Low 𝑛 = 96 80 60.5–104.4 6.9 5.1–9.0 11.6 8.4–15.6
Atrophy High 𝑛 = 11 68.3 40.6–125.1 10.1
∗ 7.5–11.6 8.1 4.5–16.5
Low 𝑛 = 104 80.0 59.4 6.9 5.1–9.0 11.3 8.2–14.6
Intestinal metaplasia High 𝑛 = 8 38.1
∗∗ 25.8–93.5 7.8 4.7–12.8 4.1∗ 2.5–15.0
Low 𝑛 = 107 78.4 59.6–103.1 7.1 5.3–9.4 11.3 8.2–14.7
1Low score: normal or mild changes; high score: moderate or marked changes.
2IQR: interquartile range expressed as percentile 25–75.
∗
𝑃 < 0.05& ∗∗𝑃 < 0.01 when pepsinogen concentrations (or pepsinogen ratio) were compared in groups of high and low histology scores (Mann-Whitney𝑈
test).
those with low grade IM in corpus (𝑃 < 0.01 and 𝑃 < 0.05
resp.) (Table 3).
In the patients with persistent H. pylori infection in
spite of therapy, the neutrophil cell infiltration was remark-
ably reduced, but the number of subjects with high grade
mononuclear cell infiltration in antrum and corpus remained
high. Serum pepsinogen II level increased more in those
subjects with severe mononuclear cell infiltration compared
to subjects with mild infiltration in antrum and corpus (𝑃 <
0.001) (Table 4).
High grade atrophy in corpus but not in antrum affected
the serum level of pepsinogen II in all groups before and after
eradication. (Tables 2, 3, and 4).
5. Discussion
Pepsinogens are produced in the gastric mucosa and their
secretion is increased by H. pylori-induced gastritis. After
eradication ofH. pylori infection with antibiotics and regres-
sion of inflammation, both pepsinogens decreased after a
few weeks [12–21] and remained unchanged over one year
[16, 17, 21].
Apart from studies about the relationship between low
serum level of pepsinogen I and low ratio of pepsinogen
I to II in atrophic gastritis in corpus [1, 24–29], there are
few reports about the type and intensity of morphologic
changes and their localization in antrum or corpus in relation
to the levels of both serum pepsinogens. It is unknown
how the eradication of H. pylori and its long term effect
on morphological changes influences the level of serum
biomarkers, when the inflammation regresses or disappears.
In studies with a small number of subjects, an increase
in both pepsinogens is reported to be the result of severe
inflammation only in antrum [11, 30]. Another small study of
this kind showed that high pepsinogen I level is found only
in cases with severe inflammation in antrum and corpus [31].
In a large study with 283 subjects, 139 with H. pylori
infection, Kiyohira et al. reported that severity of polymor-
phonuclear ormononuclear cell infiltration,mucosal atrophy,
and intestinal metaplasia were associated with an increase
in pepsinogen II and to a lesser degree in pepsinogen I as
well as a decrease in pepsinogen I to II ratio. Pepsinogen
II level more than 12 𝜇g/mL and a pepsinogen I to II ratio
less than 4 had a high sensitivity and specificity for H. pylori
gastritis. However, in this large study, the topography of the
morphological changes was not noted [8].
Our study revealed that the severity of inflammatory
cell infiltration and the other morphological features in
antrum or corpus do not generally affect the level of serum
pepsinogen I neither before nor after successful eradication
or in case of persistent infection. By contrast, the grade
of all morphological characteristics in corpus affects the
serum level of pepsinogen II. The comparison of the level of
BioMed Research International 5
Table 4: Concentrations of pepsinogen I, pepsinogen II, and pepsinogen I to II ratio according to histological categories1 in antrum and
corpus in first-degree relatives of patients with gastric adenocarcinoma in the control group & those with failed H. pylori eradication from
the treatment group (𝑛 = 245).
Pepsinogen I (𝜇g/mL) Pepsinogen II (𝜇g/mL) Pepsinogen ratio
Median IQR2 Median IQR Median IQR
Antrum
Neutrophil cell
infiltration
High 𝑛 = 46 108.2 78.4–153.2 11.8 8.5–23.0 8.4 5.7–10.8
Low 𝑛 = 199 123.6 82.5–164.4 15.3 9.8–27.3 7.0 4.6–11.6
Mononuclear
cell infiltration
High 𝑛 = 224 122.5 83.0–164.3 15.3∗ 9.5–26.4 7.1 4.8–11.1
Low 𝑛 = 21 93.6 77.3–140.6 10.4 7.7–18.7 10.9 5.0–13.7
Atrophy High 𝑛 = 58 126.9 88.0–166.5 14.8 8.1–26.3 8.2 5.0–12.5
Low 𝑛 = 187 120.9 81.7–160.7 15.2 9.7–26.3 7.0 4.8–10.9
Intestinal metaplasia High 𝑛 = 29 119.5 69.1–175.7 16.0 11.0–28.6 5.1
∗ 4.0–8.6
Low 𝑛 = 216 122.2 82.6–161.5 14.9 9.0–25.7 7.6 5.0–11.7
Corpus
Neutrophil cell
infiltration
High 𝑛 = 38 149.0∗ 105.9–192.4 24.4∗∗∗ 11.4–41.2 5.2∗∗ 3.7–9.0
Low 𝑛 = 207 118.2 81.3–157.4 14.7 8.9–23.9 7.6 5.1–11.8
Mononuclear cell
infiltration
High 𝑛 = 172 123.2 82.2–164.3 18.1∗∗∗ 10.4–27.8 6.7∗∗∗ 4.3–10.1
Low 𝑛 = 73 109.1 82.1–159.0 11.5 7.9–19.3 9.9 5.9–12.5
Atrophy High 𝑛 = 43 121.8 80.2–121.8 22.3
∗ 11.1–31.5 5.7∗ 3.8–10.7
Low 𝑛 = 202 122.0 82.8–158.6 14.8 8.9–24.2 7.7 5.0–11.6
Intestinal metaplasia High 𝑛 = 19 124.9 74.2–198.0 24.0 11.2–30.3 5.7
∗ 3.9–7.8
Low 𝑛 = 226 121.8 82.5–160.9 14.8 8.9–24.9 7.6 5.0–11.6
1Low score: normal or mild changes; high score: moderate or marked changes.
2IQR: interquartile range expressed as percentile 25–75.
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 when pepsinogen concentrations (or pepsinogen ratio) were compared in groups of high and low histology scores
(Mann-Whitney 𝑈 test).
serum pepsinogens I and II with the level after eradication
revealed that inflammatory cell infiltration in antrum and
corpus both contribute mainly to the high synthesis of both
biomarkers in gastric mucosa, the delivery into circulation,
and to their high serum concentration. Their serum levels
before H. pylori eradication are not related to the severity
of different morphological changes in antrum. It seems that
H. pylori-induced inflammation conceals the relationship
between the low level of pepsinogen I and atrophy as well
as intestinal metaplasia localized in corpus. However, after
successful eradication and complete regression of neutrophil
cell infiltration, the relationship between pepsinogen I and
the severity of intestinal metaplasia in corpus emerged.
The serum level of pepsinogen II is related to the grade
of different morphological characteristics in corpus before
eradication. After H. pylori eradication, the neutrophil cells
disappeared almost completely both in antrum and corpus.
The 55% decrease of the level of pepsinogen II may suggest
that it is mainly the result of disappearance of neutrophil
cell infiltration caused by treatment of H. pylori infection.
The mononuclear cell infiltration decreases after eradication
but remains moderately present in one-sixth of patients both
in antrum and corpus. The increased pepsinogen II level in
serum after eradication seems to be dependent on the severity
of mononuclear cell infiltration and atrophy in corpus. The
clinical relevance of atrophic gastritis in corpus after eradica-
tion of H. pylori and its natural development are unknown.
As gastric carcinoma can occur despite H. pylori eradication
[32], the importance of this chronic atrophic inflammation in
corpus for the development and progression of precancerous
conditions, such as mucosal atrophy or intestinal metaplasia,
requires more investigation. If this type of corpus gastritis
plays a role in the advancement of precancerous conditions,
then screening of pepsinogen II could achieve diagnostic
value as a marker of atrophic corpus gastritis after H. pylori
eradication in the patients at risk of gastric cancer.
High serum pepsinogen II has been neglected for long
time in clinical research and has not been considered as a
marker of H. pylori-induced gastritis. The remarkable 55%
decrease of pepsinogen II level in our study for successful
eradication and its non-normalized level after successful
eradication suggest its relevance as an appropriate marker of
the evaluation of H. pylori related and H. pylori-free gastric
diseases.
One limitation of our study is the low number of patients
with advanced type of IM in corpus. Therefore, we could
not find an inverse relationship between low serum level
of pepsinogen I and high grade of IM in corpus before H.
pylori eradication. It is possible that the high accumulation
of inflammatory cells due to the presence of H. pylori
infection in the stomach as stimulant factor for secretion of
the biomarkers conceals the occurrence of this relationship.
When the atrophic gastritis advances in corpus and H. pylori
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infection disappears, the relationship becomes clear, as we
found after H. pylori eradication.
In conclusion, high serumpepsinogen II is a goodmarker
for H. pylori-induced gastritis in causal connection with the
neutrophil and mononuclear cell infiltration mainly in cor-
pus. Its subsequent drop is also a good marker of successful
eradication. Its high level afterH. pylori eradication might be
a marker of the presence of atrophic corpus gastritis. When
this type of gastritis is associated with intestinal metaplasia,
both serum pepsinogen I level and pepsinogen I to II ratio
will decrease.
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